By Josh Beckerman

 

The U.S. Food and Drug Administration expanded its emergency use authorization for a combination of two Eli Lilly & Co. monoclonal antibodies for treating mild to moderate Covid-19, expanding authorization to all ages including newborns for those who are at high risk for progression to severe Covid-19.

The combination of bamlanivimab and etesevimab was previously authorized for people 12 years of age and older weighing at least 40 kilograms.

Lilly said it is "working quickly to understand neutralization activity of our therapies on the Omicron variant of concern."

 

Write to Josh Beckerman at josh.beckerman@wsj.com

 

(END) Dow Jones Newswires

December 03, 2021 15:18 ET (20:18 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Eli Lilly Charts.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Eli Lilly Charts.